Defence Therapeutics (XCNQ:DTC) EPS (Basic) : C$-0.27 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics EPS (Basic)?

Defence Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was C$-0.19. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.27.

Defence Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was C$-0.19. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.27.

Defence Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was C$-0.19. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.27.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Defence Therapeutics EPS (Basic) Historical Data

The historical data trend for Defence Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics EPS (Basic) Chart

Defence Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

EPS (Basic)

-0.02

-0.11

-0.20

Defence Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial										-0.05	-0.05	-0.03	-0.05	-0.19

Defence Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Defence Therapeutics's Basic EPS for the fiscal year that ended in Jun. 2022 is calculated as

Basic EPS (A: Jun. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-7.344	-	0)	/	36.077
	=	-0.20

Defence Therapeutics's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.32	-	0)	/	44.098
	=	-0.19

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.27

Defence Therapeutics (XCNQ:DTC) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Defence Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

DTCFF:USA DTC:Germany

Address

200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6

Website

https://www.defencetherapeutics.com

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.